{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:36:23Z","timestamp":1790397383174,"version":"4.1.0"},"reference-count":248,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41573-025-01335-w","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T11:53:11Z","timestamp":1767873191000},"page":"310-330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Novel drug treatments for schizophrenia"],"prefix":"10.1038","volume":"25","author":[{"given":"Joseph T.","family":"Coyle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2773-8025","authenticated-orcid":false,"given":"Steven M.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"1335_CR1","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1001\/archpsyc.1996.01830110060007","volume":"53","author":"KS Kendler","year":"1996","unstructured":"Kendler, K. S., Gallagher, T. J., Abelson, J. M. & Kessler, R. C. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The national comorbidity survey. Arch. Gen. Psychiatry 53, 1022\u20131031 (1996).","journal-title":"Arch. Gen. Psychiatry"},{"key":"1335_CR2","doi-asserted-by":"publisher","first-page":"22m14458","DOI":"10.4088\/JCP.22m14458","volume":"83","author":"A Kadakia","year":"2022","unstructured":"Kadakia, A. et al. The economic burden of schizophrenia in the United States. J. Clin. Psychiatry 83, 22m14458 (2022).","journal-title":"J. Clin. Psychiatry"},{"key":"1335_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1093\/oxfordjournals.schbul.a007078","volume":"30","author":"M Knapp","year":"2004","unstructured":"Knapp, M., Mangalore, R. & Simon, J. The global costs of schizophrenia. Schizophr. Bull. 30, 279\u2013293 (2004).","journal-title":"Schizophr. Bull."},{"key":"1335_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.schres.2012.01.030","volume":"136","author":"BA Fischer","year":"2012","unstructured":"Fischer, B. A. et al. Cortical structural abnormalities in deficit versus nondeficit schizophrenia. Schizophr. Res. 136, 51\u201354 (2012).","journal-title":"Schizophr. Res."},{"key":"1335_CR5","unstructured":"Corsellis, J. A. N. in Greenfield\u2019s Neuropathology 3rd edn (eds Blackwood, W. & Corsellis, J. A. N.) 903\u2013915 (1976)."},{"key":"1335_CR6","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/archpsyc.1982.04290100011003","volume":"39","author":"JR Stevens","year":"1982","unstructured":"Stevens, J. R. Neuropathology of schizophrenia. Arch. Gen. Psychiatry 39, 1131\u20131139 (1982).","journal-title":"Arch. Gen. Psychiatry"},{"key":"1335_CR7","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S0140-6736(76)90890-4","volume":"2","author":"EC Johnstone","year":"1976","unstructured":"Johnstone, E. C., Crow, T. J., Frith, C. D., Husband, J. & Kreel, L. Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet 2, 924\u2013926 (1976).","journal-title":"Lancet"},{"key":"1335_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1001\/archpsyc.55.3.215","volume":"55","author":"G Rajkowska","year":"1998","unstructured":"Rajkowska, G., Selemon, L. D. & Goldman-Rakic, P. S. Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch. Gen. Psychiatry 55, 215\u2013224 (1998).","journal-title":"Arch. Gen. Psychiatry"},{"key":"1335_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0006-3223(98)00281-9","volume":"45","author":"LD Selemon","year":"1999","unstructured":"Selemon, L. D. & Goldman-Rakic, P. S. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol. Psychiatry 45, 17\u201325 (1999).","journal-title":"Biol. Psychiatry"},{"key":"1335_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.neuroscience.2015.06.028","volume":"303","author":"K Bakhshi","year":"2015","unstructured":"Bakhshi, K. & Chance, S. A. The neuropathology of schizophrenia: a selective review of past studies and emerging themes in brain structure and cytoarchitecture. Neuroscience 303, 82\u2013102 (2015).","journal-title":"Neuroscience"},{"key":"1335_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0920-9964(01)00201-8","volume":"55","author":"MF Casanova","year":"2002","unstructured":"Casanova, M. F. & Rothberg, B. Shape distortion of the hippocampus: a possible explanation of the pyramidal cell disarray reported in schizophrenia. Schizophr. Res. 55, 19\u201324 (2002).","journal-title":"Schizophr. Res."},{"key":"1335_CR12","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1001\/jamapsychiatry.2014.1582","volume":"71","author":"GT Konopaske","year":"2014","unstructured":"Konopaske, G. T., Lange, N., Coyle, J. T. & Benes, F. M. Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder. JAMA Psychiatry 71, 1323\u20131331 (2014).","journal-title":"JAMA Psychiatry"},{"key":"1335_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/HRP.0000000000000102","volume":"24","author":"JT Coyle","year":"2016","unstructured":"Coyle, J. T., Balu, D. T., Puhl, M. D. & Konopaske, G. T. History of the concept of disconnectivity in schizophrenia. Harv. Rev. Psychiatry 24, 80\u201386 (2016).","journal-title":"Harv. Rev. Psychiatry"},{"key":"1335_CR14","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1176\/appi.ajp.2019.19020151","volume":"176","author":"M McHugo","year":"2019","unstructured":"McHugo, M. et al. Hyperactivity and reduced activation of anterior hippocampus in early psychosis. Am. J. Psychiatry 176, 1030\u20131038 (2019). This study demonstrates disinhibition of excitatory neurons in the hippocampus in schizophrenia.","journal-title":"Am. J. Psychiatry"},{"key":"1335_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41582-023-00904-0","volume":"20","author":"OD Howes","year":"2024","unstructured":"Howes, O. D., Bukala, B. R. & Beck, K. Schizophrenia: from neurochemistry to circuits, symptoms and treatments. Nat. Rev. Neurol. 20, 22\u201335 (2024).","journal-title":"Nat. Rev. Neurol."},{"key":"1335_CR16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.tins.2008.02.005","volume":"31","author":"JE Lisman","year":"2008","unstructured":"Lisman, J. E. et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 31, 234\u2013242 (2008). This paper summarizes the evidence that the psychotic effects of NMDAR blockade result from differential sensitivity of cortical PV+GABAergic neurons, defining a pathologic circuit.","journal-title":"Trends Neurosci."},{"key":"1335_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.biopsycho.2015.10.013","volume":"116","author":"VS Catts","year":"2016","unstructured":"Catts, V. S., Lai, Y. L., Weickert, C. S., Weickert, T. W. & Catts, S. V. A quantitative review of the postmortem evidence for decreased cortical N-methyl-D-aspartate receptor expression levels in schizophrenia: how can we link molecular abnormalities to mismatch negativity deficits? Biol. Psychol. 116, 57\u201367 (2016).","journal-title":"Biol. Psychol."},{"key":"1335_CR18","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3390\/cells12040574","volume":"12","author":"A de Bartolomeis","year":"2023","unstructured":"de Bartolomeis, A. et al. Dysregulated signaling at postsynaptic density: a systematic review and translational appraisal for the pathophysiology, clinics, and antipsychotics\u2019 treatment of schizophrenia. Cells 12, 574 (2023).","journal-title":"Cells"},{"key":"1335_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4062\/biomolther.2012.20.1.001","volume":"20","author":"MD Rubio","year":"2012","unstructured":"Rubio, M. D., Drummond, J. B. & Meador-Woodruff, J. H. Glutamate receptor abnormalities in schizophrenia: implications for innovative treatments. Biomol. Ther. 20, 1\u201318 (2012). A review of the evidence of glutamatergic function in schizophrenia.","journal-title":"Biomol. Ther."},{"key":"1335_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3389\/fncel.2013.00095","volume":"7","author":"G Chana","year":"2013","unstructured":"Chana, G. et al. Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis. Front. Cell. Neurosci. 7, 95 (2013).","journal-title":"Front. Cell. Neurosci."},{"key":"1335_CR21","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/brain\/122.4.593","volume":"122","author":"PJ Harrison","year":"1999","unstructured":"Harrison, P. J. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122, 593\u2013624 (1999).","journal-title":"Brain"},{"key":"1335_CR22","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1038\/s41380-023-02293-8","volume":"28","author":"MJ Owen","year":"2023","unstructured":"Owen, M. J., Legge, S. E., Rees, E., Walters, J. T. & O\u2019Donovan, M. C. Genomic findings in schizophrenia and their implications. Mol. Psych. 28, 3638\u20133647 (2023).","journal-title":"Mol. Psych."},{"key":"1335_CR23","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/s41586-022-04434-5","volume":"604","author":"V Trubetskoy","year":"2022","unstructured":"Trubetskoy, V. et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature 604, 502\u2013508 (2022).","journal-title":"Nature"},{"key":"1335_CR24","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1126\/science.aaa8954","volume":"349","author":"DH Geschwind","year":"2015","unstructured":"Geschwind, D. H. & Flint, J. Genetics and genomics of psychiatric disease. Science 349, 1489\u20131494 (2015).","journal-title":"Science"},{"key":"1335_CR25","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41586-022-04556-w","volume":"604","author":"T Singh","year":"2022","unstructured":"Singh, T. et al. Rare coding variants in ten genes confer substantial risk for schizophrenia. Nature 604, 509\u2013516 (2022). A study using exome sequencing that has identified rare loss-of-function mutations in two glutamate receptor subunits that markedly increase the risk of schizophrenia.","journal-title":"Nature"},{"key":"1335_CR26","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1038\/s41380-023-02005-2","volume":"28","author":"T Nakamura","year":"2023","unstructured":"Nakamura, T. & Takata, A. The molecular pathology of schizophrenia: an overview of existing knowledge and new directions for future research. Mol. Psychiatry 28, 1868\u20131889 (2023).","journal-title":"Mol. Psychiatry"},{"key":"1335_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41588-023-01305-1","volume":"55","author":"D Liu","year":"2023","unstructured":"Liu, D. et al. Schizophrenia risk conferred by rare protein-truncating variants is conserved across diverse human populations. Nat. Genet. 55, 369\u2013376 (2023).","journal-title":"Nat. Genet."},{"key":"1335_CR28","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.nbd.2011.10.006","volume":"45","author":"DT Balu","year":"2012","unstructured":"Balu, D. T., Basu, A. C., Corradi, J. P., Cacace, A. M. & Coyle, J. T. The NMDA receptor co-agonists, D-serine and glycine, regulate neuronal dendritic architecture in the somatosensory cortex. Neurobiol. Dis. 45, 671\u2013682 (2012).","journal-title":"Neurobiol. Dis."},{"key":"1335_CR29","doi-asserted-by":"publisher","first-page":"E2400","DOI":"10.1073\/pnas.1304308110","volume":"110","author":"DT Balu","year":"2013","unstructured":"Balu, D. T. et al. Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. Proc. Natl Acad. Sci. USA 110, E2400\u2013E2409 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1335_CR30","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41593-020-00763-8","volume":"24","author":"M Yilmaz","year":"2021","unstructured":"Yilmaz, M. et al. Overexpression of schizophrenia susceptibility factor human complement C4A promotes excessive synaptic loss and behavioral changes in mice. Nat. Neurosci. 24, 214\u2013224 (2021).","journal-title":"Nat. Neurosci."},{"key":"1335_CR31","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1093\/ijnp\/pyad011","volume":"26","author":"JT Kantrowitz","year":"2023","unstructured":"Kantrowitz, J. T., Correll, C. U., Jain, R. & Cutler, A. J. New developments in the treatment of schizophrenia: an expert roundtable. Int. J. Neuropsychopharmacol. 26, 322\u2013330 (2023).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"1335_CR32","doi-asserted-by":"publisher","first-page":"102815","DOI":"10.1016\/j.conb.2023.102815","volume":"83","author":"L Mony","year":"2023","unstructured":"\u00a0Mony, L. & Paoletti, P. Mechanisms of NMDA receptor regulation. Curr Opin Neurobiol.\u00a083, 102815 (2023).","journal-title":"Curr Opin Neurobiol."},{"key":"1335_CR33","doi-asserted-by":"publisher","first-page":"108711","DOI":"10.1016\/j.neuropharm.2021.108711","volume":"196","author":"J Baranovic","year":"2021","unstructured":"Baranovic, J. AMPA receptors in the synapse: very little space and even less time. Neuropharmacology 196, 108711 (2021).","journal-title":"Neuropharmacology"},{"key":"1335_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55635-4","volume":"9","author":"M Koromina","year":"2019","unstructured":"Koromina, M., Flitton, M., Blockley, A., Mellor, I. R. & Knight, H. M. Damaging coding variants within kainate receptor channel genes are enriched in individuals with schizophrenia, autism and intellectual disabilities. Sci. Rep. 9, 19215 (2019).","journal-title":"Sci. Rep."},{"key":"1335_CR35","doi-asserted-by":"publisher","first-page":"102815","DOI":"10.1016\/j.conb.2023.102815","volume":"83","author":"L Mony","year":"2023","unstructured":"Mony, L. & Paoletti, P. Mechanisms of NMDA receptor regulation. Curr. Opin. Neurobiol. 83, 102815 (2023).","journal-title":"Curr. Opin. Neurobiol."},{"key":"1335_CR36","doi-asserted-by":"publisher","first-page":"108631","DOI":"10.1016\/j.neuropharm.2021.108631","volume":"193","author":"D Stroebel","year":"2021","unstructured":"Stroebel, D., Mony, L. & Paoletti, P. Glycine agonism in ionotropic glutamate receptors. Neuropharmacology 193, 108631 (2021).","journal-title":"Neuropharmacology"},{"key":"1335_CR37","doi-asserted-by":"crossref","unstructured":"Seeburg, P. H. et al. The NMDA receptor channel: molecular design of a coincidence detector. In Recent Progress in Hormone Research, Proc. 1993 Laurentian Hormone Conference (ed. Bardin, C. W.) 19\u201334 (Academic Press, 1995).","DOI":"10.1016\/B978-0-12-571150-0.50006-8"},{"key":"1335_CR38","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00441-006-0266-5","volume":"326","author":"F Ferraguti","year":"2006","unstructured":"Ferraguti, F. & Shigemoto, R. Metabotropic glutamate receptors. Cell Tissue Res. 326, 483\u2013504 (2006).","journal-title":"Cell Tissue Res."},{"key":"1335_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2017.172","volume":"7","author":"SM Saini","year":"2017","unstructured":"Saini, S. M. et al. Meta-analysis supports GWAS-implicated link between GRM3 and schizophrenia risk. Transl. Psychiatry 7, e1196 (2017).","journal-title":"Transl. Psychiatry"},{"key":"1335_CR40","doi-asserted-by":"publisher","first-page":"7503","DOI":"10.1523\/JNEUROSCI.17-19-07503.1997","volume":"17","author":"R Shigemoto","year":"1997","unstructured":"Shigemoto, R. et al. Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J. Neurosci. 17, 7503\u20137522 (1997).","journal-title":"J. Neurosci."},{"key":"1335_CR41","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1001\/archneurpsyc.1959.02340150095011","volume":"81","author":"ED Luby","year":"1959","unstructured":"Luby, E. D., Cohen, B. D., Rosenbaum, G., Gottlieb, J. S. & Kelley, R. Study of a new schizophrenomimetic drug; sernyl. Arch. Neurol. Psychiatry 81, 363\u2013369 (1959).","journal-title":"Arch. Neurol. Psychiatry"},{"key":"1335_CR42","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","volume":"148","author":"DC Javitt","year":"1991","unstructured":"Javitt, D. C. & Zukin, S. R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148, 1301\u20131308 (1991). The authors review the evidence that ketamine, a dissociative anaesthetic that blocks NMDARs, replicates the symptoms of schizophrenia.","journal-title":"Am. J. Psychiatry"},{"key":"1335_CR43","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1001\/archpsyc.59.7.663","volume":"59","author":"JH Krystal","year":"2002","unstructured":"Krystal, J. H., Anand, A. & Moghaddam, B. Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia. Arch. Gen. Psychiatry 59, 663\u2013664 (2002).","journal-title":"Arch. Gen. Psychiatry"},{"key":"1335_CR44","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0006-3223(01)01242-2","volume":"51","author":"D Umbricht","year":"2002","unstructured":"Umbricht, D., Koller, R., Vollenweider, F. X. & Schmid, L. Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol. Psychiatry 51, 400\u2013406 (2002).","journal-title":"Biol. Psychiatry"},{"key":"1335_CR45","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0924-977X(96)00039-9","volume":"7","author":"FX Vollenweider","year":"1997","unstructured":"Vollenweider, F. X. et al. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur. Neuropsychopharmacol. 7, 9\u201324 (1997).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"1335_CR46","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0022-3956(99)00031-X","volume":"34","author":"FX Vollenweider","year":"2000","unstructured":"Vollenweider, F. X., Vontobel, P., \u00d8ye, I., Hell, D. & Leenders, K. L. Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. J. Psychiatr. Res. 34, 35\u201343 (2000).","journal-title":"J. Psychiatr. Res."},{"key":"1335_CR47","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1093\/schbul\/sbs075","volume":"38","author":"B Moghaddam","year":"2012","unstructured":"Moghaddam, B. & Krystal, J. H. Capturing the angel in \u201cangel dust\u201d: twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr. Bull. 38, 942\u2013949 (2012).","journal-title":"Schizophr. Bull."},{"key":"1335_CR48","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1126\/science.32620","volume":"203","author":"MV Johnston","year":"1979","unstructured":"Johnston, M. V., Grzanna, R. & Coyle, J. T. Methylazoxymethanol treatment of fetal rats results in abnormally dense noradrenergic innervation of neocortex. Science 203, 369\u2013371 (1979).","journal-title":"Science"},{"key":"1335_CR49","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.biopsych.2015.11.007","volume":"81","author":"AA Grace","year":"2017","unstructured":"Grace, A. A. Dopamine system dysregulation and the pathophysiology of schizophrenia: insights from the methylazoxymethanol acetate model. Biol. Psychiatry 81, 5\u20138 (2017).","journal-title":"Biol. Psychiatry"},{"key":"1335_CR50","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/adb.12577","volume":"24","author":"MD Puhl","year":"2019","unstructured":"Puhl, M. D. et al. N-Methyl-d-aspartate receptor co-agonist availability affects behavioral and neurochemical responses to cocaine: insights into comorbid schizophrenia and substance abuse. Addict. Biol. 24, 40\u201350 (2019).","journal-title":"Addict. Biol."},{"key":"1335_CR51","doi-asserted-by":"publisher","first-page":"13409","DOI":"10.1073\/pnas.96.23.13409","volume":"96","author":"H Wolosker","year":"1999","unstructured":"Wolosker, H., Blackshaw, S. & Snyder, S. H. Serine racemase: a glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission. Proc. Natl Acad. Sci. USA 96, 13409\u201313414 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1335_CR52","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.tins.2016.09.007","volume":"39","author":"H Wolosker","year":"2016","unstructured":"Wolosker, H., Balu, D. T. & Coyle, J. T. The rise and fall of the D-serine-mediated gliotransmission hypothesis. Trends Neurosci. 39, 712\u2013721 (2016).","journal-title":"Trends Neurosci."},{"key":"1335_CR53","doi-asserted-by":"publisher","first-page":"9564","DOI":"10.1523\/JNEUROSCI.1525-20.2020","volume":"40","author":"JM Wong","year":"2020","unstructured":"Wong, J. M. et al. Postsynaptic serine racemase regulates NMDA receptor function. J. Neurosci. 40, 9564\u20139575 (2020).","journal-title":"J. Neurosci."},{"key":"1335_CR54","doi-asserted-by":"publisher","first-page":"104511","DOI":"10.1016\/j.nbd.2019.104511","volume":"130","author":"DT Balu","year":"2019","unstructured":"Balu, D. T. et al. Neurotoxic astrocytes express the d-serine synthesizing enzyme, serine racemase, in Alzheimer\u2019s disease. Neurobiol. Dis. 130, 104511 (2019).","journal-title":"Neurobiol. Dis."},{"key":"1335_CR55","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1172\/JCI92300","volume":"127","author":"EJ Perez","year":"2017","unstructured":"Perez, E. J. et al. Enhanced astrocytic d-serine underlies synaptic damage after traumatic brain injury. J. Clin. Investig. 127, 3114\u20133125 (2017).","journal-title":"J. Clin. Investig."},{"key":"1335_CR56","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.schres.2012.09.014","volume":"142","author":"MA Calcia","year":"2012","unstructured":"Calcia, M. A. et al. Plasma levels of D-serine in Brazilian individuals with schizophrenia. Schizophr. Res. 142, 83\u201387 (2012).","journal-title":"Schizophr. Res."},{"key":"1335_CR57","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.pnpbp.2005.04.023","volume":"29","author":"K Hashimoto","year":"2005","unstructured":"Hashimoto, K. et al. Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 29, 767\u2013769 (2005).","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"1335_CR58","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1038\/s41380-019-0401-9","volume":"25","author":"J Kindler","year":"2020","unstructured":"Kindler, J. et al. Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia. Mol. Psychiatry 25, 2860\u20132872 (2020).","journal-title":"Mol. Psychiatry"},{"key":"1335_CR59","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/schbul\/sbq112","volume":"37","author":"KV Sathyasaikumar","year":"2011","unstructured":"Sathyasaikumar, K. V. et al. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr. Bull. 37, 1147\u20131156 (2011).","journal-title":"Schizophr. Bull."},{"key":"1335_CR60","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/S0006-3223(98)00237-6","volume":"45","author":"DC Javitt","year":"1999","unstructured":"Javitt, D. C., Balla, A., Sershen, H. & Lajtha, A. A. E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Biol. Psychiatry 45, 668\u2013679 (1999).","journal-title":"Biol. Psychiatry"},{"key":"1335_CR61","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrn3257","volume":"13","author":"R Schwarcz","year":"2012","unstructured":"Schwarcz, R., Bruno, J. P., Muchowski, P. J. & Wu, H. Q. Kynurenines in the mammalian brain: when physiology meets pathology. Nat. Rev. Neurosci. 13, 465\u2013477 (2012). Kynurenic acid, an endogenous allosteric inhibitor of NMDAR 63.","journal-title":"Nat. Rev. Neurosci."},{"key":"1335_CR62","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1093\/schbul\/sbw221","volume":"43","author":"E Plitman","year":"2017","unstructured":"Plitman, E. et al. Kynurenic acid in schizophrenia: a systematic review and meta-analysis. Schizophr. Bull. 43, 764\u2013777 (2017).","journal-title":"Schizophr. Bull."},{"key":"1335_CR63","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.2174\/1568026611209061797","volume":"12","author":"L Szalardy","year":"2012","unstructured":"Szalardy, L. et al. Manipulating kynurenic acid levels in the brain - on the edge between neuroprotection and cognitive dysfunction. Curr. Top. Med. Chem. 12, 1797\u20131806 (2012).","journal-title":"Curr. Top. Med. Chem."},{"key":"1335_CR64","doi-asserted-by":"publisher","first-page":"10592","DOI":"10.1523\/JNEUROSCI.1107-14.2014","volume":"34","author":"R Kozak","year":"2014","unstructured":"Kozak, R. et al. Reduction of brain kynurenic acid improves cognitive function. J. Neurosci. 34, 10592\u201310602 (2014).","journal-title":"J. Neurosci."},{"key":"1335_CR65","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hipo.23040","volume":"29","author":"A Pocivavsek","year":"2019","unstructured":"Pocivavsek, A., Elmer, G. I. & Schwarcz, R. Inhibition of kynurenine aminotransferase II attenuates hippocampus-dependent memory deficit in adult rats treated prenatally with kynurenine. Hippocampus 29, 73\u201377 (2019).","journal-title":"Hippocampus"},{"key":"1335_CR66","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/cercor\/bhh147","volume":"15","author":"B Cubelos","year":"2005","unstructured":"Cubelos, B., Gim\u00e9nez, C. & Zafra, F. Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain. Cereb. Cortex 15, 448\u2013459 (2005).","journal-title":"Cereb. Cortex"},{"key":"1335_CR67","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.biopsych.2003.09.012","volume":"55","author":"G Tsai","year":"2004","unstructured":"Tsai, G., Lane, H. Y., Yang, P., Chong, M. Y. & Lange, N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 55, 452\u2013456 (2004).","journal-title":"Biol. Psychiatry"},{"key":"1335_CR68","doi-asserted-by":"publisher","first-page":"20736","DOI":"10.1073\/pnas.1909458116","volume":"116","author":"S Neame","year":"2019","unstructured":"Neame, S. et al. The NMDA receptor activation by d-serine and glycine is controlled by an astrocytic Phgdh-dependent serine shuttle. Proc. Natl Acad. Sci. USA 116, 20736\u201320742 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1335_CR69","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2174\/092986706776360932","volume":"13","author":"LG Harsing Jr","year":"2006","unstructured":"Harsing, L. G. Jr et al. Glycine transporter type-1 and its inhibitors. Curr. Med. Chem. 13, 1017\u20131044 (2006).","journal-title":"Curr. Med. Chem."},{"key":"1335_CR70","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1038\/sj.bjp.0704381","volume":"134","author":"KR Aubrey","year":"2001","unstructured":"Aubrey, K. R. & Vandenberg, R. J. N[3-(4\u2032-fluorophenyl)-3-(4\u2032-phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transport. Br. J. Pharmacol. 134, 1429\u20131436 (2001).","journal-title":"Br. J. Pharmacol."},{"key":"1335_CR71","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/JCP.0000000000000073","volume":"34","author":"JH Schoemaker","year":"2014","unstructured":"Schoemaker, J. H., Jansen, W. T., Schipper, J. & Szegedi, A. The selective glycine uptake inhibitor Org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial. J. Clin. Psychopharmacol. 34, 190\u2013198 (2014).","journal-title":"J. Clin. Psychopharmacol."},{"key":"1335_CR72","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jamapsychiatry.2014.163","volume":"71","author":"D Umbricht","year":"2014","unstructured":"Umbricht, D. et al. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatry 71, 637\u2013646 (2014).","journal-title":"JAMA Psychiatry"},{"key":"1335_CR73","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S2215-0366(16)30344-3","volume":"3","author":"D Bugarski-Kirola","year":"2016","unstructured":"Bugarski-Kirola, D. et al. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. Lancet Psychiatry 3, 1115\u20131128 (2016).","journal-title":"Lancet Psychiatry"},{"key":"1335_CR74","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.biopsych.2017.12.019","volume":"84","author":"DC D\u2019Souza","year":"2018","unstructured":"D\u2019Souza, D. C. et al. Dose-related target occupancy and effects on circuitry, behavior, and neuroplasticity of the glycine transporter-1 inhibitor PF-03463275 in healthy and schizophrenia subjects. Biol. Psychiatry 84, 413\u2013421 (2018).","journal-title":"Biol. Psychiatry"},{"key":"1335_CR75","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.schres.2023.04.010","volume":"256","author":"TS Surti","year":"2023","unstructured":"Surti, T. S. et al. Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia. Schizophr. Res. 256, 36\u201343 (2023).","journal-title":"Schizophr. Res."},{"key":"1335_CR76","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s00406-023-01576-z","volume":"273","author":"H Rosenbrock","year":"2023","unstructured":"Rosenbrock, H., Desch, M. & Wunderlich, G. Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 273, 1557\u20131566 (2023).","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"1335_CR77","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","volume":"17","author":"B Moghaddam","year":"1997","unstructured":"Moghaddam, B., Adams, B., Verma, A. & Daly, D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17, 2921\u20132927 (1997).","journal-title":"J. Neurosci."},{"key":"1335_CR78","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00213-007-0974-x","volume":"196","author":"ML Woolley","year":"2008","unstructured":"Woolley, M. L., Pemberton, D. J., Bate, S., Corti, C. & Jones, D. N. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2\/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology 196, 431\u2013440 (2008).","journal-title":"Psychopharmacology"},{"key":"1335_CR79","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.neuropharm.2012.06.002","volume":"66","author":"BJ Kinon","year":"2013","unstructured":"Kinon, B. J. & G\u00f3mez, J. C. Clinical development of pomaglumetad methionil: a non-dopaminergic treatment for schizophrenia. Neuropharmacology 66, 82\u201386 (2013).","journal-title":"Neuropharmacology"},{"key":"1335_CR80","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1124\/jpet.108.136861","volume":"326","author":"MJ Fell","year":"2008","unstructured":"Fell, M. J., Svensson, K. A., Johnson, B. G. & Schoepp, D. D. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2\/3 receptor agonist (\u2013)-(1 R, 4 S,5 S,6 S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J. Pharmacol. Exp. Ther. 326, 209\u2013217 (2008).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1335_CR81","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/nm1632","volume":"13","author":"ST Patil","year":"2007","unstructured":"Patil, S. T. et al. Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat. Med. 13, 1102\u20131107 (2007).","journal-title":"Nat. Med."},{"key":"1335_CR82","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.2174\/1381612821666150605105632","volume":"21","author":"GJ Marek","year":"2015","unstructured":"Marek, G. J. When is a proof-of-concept (POC) not a POC? Pomaglumetad (LY2140023) as a case study for antipsychotic efficacy. Curr. Pharm. Des. 21, 3788\u20133796 (2015).","journal-title":"Curr. Pharm. Des."},{"key":"1335_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-025-03604-z","volume":"15","author":"P Siekmeier","year":"2025","unstructured":"Siekmeier, P. & Coyle, J. T. Novel electroencephalographic biomarkers predict responders to an experimental glutamatergic agent in patients with schizophrenia. Transl. Psychiatry 15, 390 (2025).","journal-title":"Transl. Psychiatry"},{"key":"1335_CR84","doi-asserted-by":"publisher","first-page":"104257","DOI":"10.1016\/j.nbd.2018.08.016","volume":"131","author":"FC Nucifora Jr.","year":"2019","unstructured":"Nucifora, F. C. Jr., Woznica, E., Lee, B. J., Cascella, N. & Sawa, A. Treatment resistant schizophrenia: clinical, biological, and therapeutic perspectives. Neurobiol. Dis. 131, 104257 (2019).","journal-title":"Neurobiol. Dis."},{"key":"1335_CR85","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/BF03033801","volume":"14","author":"DJ Lodge","year":"2008","unstructured":"Lodge, D. J. & Grace, A. A. Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia. Neurotox. Res. 14, 97\u2013104 (2008).","journal-title":"Neurotox. Res."},{"key":"1335_CR86","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/mp.2017.190","volume":"23","author":"M Kokkinou","year":"2018","unstructured":"Kokkinou, M., Ashok, A. H. & Howes, O. D. The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders. Mol. Psychiatry 23, 59\u201369 (2018).","journal-title":"Mol. Psychiatry"},{"key":"1335_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02393-7","volume":"13","author":"LE Herzog","year":"2023","unstructured":"Herzog, L. E. et al. Mouse mutants in schizophrenia risk genes GRIN2A and AKAP11 show EEG abnormalities in common with schizophrenia patients. Transl. Psychiatry 13, 92 (2023).","journal-title":"Transl. Psychiatry"},{"key":"1335_CR88","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41380-021-01297-6","volume":"27","author":"T Nakahara","year":"2022","unstructured":"Nakahara, T. et al. Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of 1H-magnetic resonance spectroscopy studies. Mol. Psychiatry 27, 744\u2013757 (2022).","journal-title":"Mol. Psychiatry"},{"key":"1335_CR89","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1111\/j.1471-4159.2010.06722.x","volume":"113","author":"RI Westphalen","year":"2010","unstructured":"Westphalen, R. I., Yu, J., Krivitski, M., Jih, T. Y. & Hemmings, H. C. Jr Regional differences in nerve terminal Na+ channel subtype expression and Na+ channel-dependent glutamate and GABA release in rat CNS. J. Neurochem. 113, 1611\u20131620 (2010).","journal-title":"J. Neurochem."},{"key":"1335_CR90","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/ijnp\/pyad035","volume":"26","author":"R Anand","year":"2023","unstructured":"Anand, R., Turolla, A., Chinellato, G., Roy, A. & Hartman, R. D. Phase 2 results indicate evenamide, a selective modulator of glutamate release, is associated with clinically important long-term efficacy when added to an antipsychotic in patients with treatment-resistant schizophrenia. Int. J. Neuropsychopharmacol. 26, 523\u2013528 (2023).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"1335_CR91","doi-asserted-by":"publisher","first-page":"S126","DOI":"10.1093\/schbul\/sby016.312","volume":"44","author":"M Bortolato","year":"2018","unstructured":"Bortolato, M., Faravelli, L. & Anand, R. T36. The antipsychotic-like properties of evenamide (NW-3509) reflect the modulation of glutamatergic dysregulation. Schizophr. Bull. 44, S126\u2013S127 (2018).","journal-title":"Schizophr. Bull."},{"key":"1335_CR92","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.1093\/schbul\/sby016.324","volume":"44","author":"R Anand","year":"2018","unstructured":"Anand, R., Forrest, E. C., Hartman, R. D., Graham, S. M. & Faravelli, L. T48. Antipsychotic efficacy of evenamide (NW-3509) is due to modulation of glutamatergic dysregulation. Schizophr. Bull. 44, S132 (2018).","journal-title":"Schizophr. Bull."},{"key":"1335_CR93","doi-asserted-by":"publisher","first-page":"110275","DOI":"10.1016\/j.neuropharm.2024.110275","volume":"266","author":"R Anand","year":"2025","unstructured":"Anand, R. et al. Efficacy and safety of evenamide, a glutamate modulator, added to a second-generation antipsychotic in inadequately\/poorly responding patients with chronic schizophrenia: Results from a randomized, double-blind, placebo-controlled, phase 3, international clinical trial. Neuropharmacology 266, 110275 (2025).","journal-title":"Neuropharmacology"},{"key":"1335_CR94","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1176\/appi.ajp.2020.20101481","volume":"177","author":"JT Coyle","year":"2020","unstructured":"Coyle, J. T., Ruzicka, W. B. & Balu, D. T. Fifty years of research on schizophrenia: the ascendance of the glutamatergic synapse. Am. J. Psychiatry 177, 1119\u20131128 (2020).","journal-title":"Am. J. Psychiatry"},{"key":"1335_CR95","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/neu.2018.5790","volume":"36","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y. et al. A small molecule spinogenic compound enhances functional outcome and dendritic spine plasticity in a rat model of traumatic brain injury. J. Neurotrauma 36, 589\u2013600 (2019).","journal-title":"J. Neurotrauma"},{"key":"1335_CR96","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","volume":"39","author":"S Oddo","year":"2003","unstructured":"Oddo, S. et al. Triple-transgenic model of Alzheimer\u2019s disease with plaques and tangles: intracellular A\u03b2 and synaptic dysfunction. Neuron 39, 409\u2013421 (2003).","journal-title":"Neuron"},{"key":"1335_CR97","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1007\/s13311-021-01143-1","volume":"18","author":"L Trujillo-Estrada","year":"2021","unstructured":"Trujillo-Estrada, L. et al. SPG302 reverses synaptic and cognitive deficits without altering amyloid or tau pathology in a transgenic model of Alzheimer\u2019s disease. Neurotherapeutics 18, 2468\u20132483 (2021).","journal-title":"Neurotherapeutics"},{"key":"1335_CR98","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.crvi.2006.03.012","volume":"329","author":"EM Tansey","year":"2006","unstructured":"Tansey, E. M. Henry Dale and the discovery of acetylcholine. C. R. Biol. 329, 419\u2013425 (2006).","journal-title":"C. R. Biol."},{"key":"1335_CR99","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.neuron.2012.08.036","volume":"76","author":"MR Picciotto","year":"2012","unstructured":"Picciotto, M. R., Higley, M. J. & Mineur, Y. S. Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior. Neuron 76, 116\u2013129 (2012).","journal-title":"Neuron"},{"key":"1335_CR100","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/npp.2011.199","volume":"37","author":"CK Jones","year":"2012","unstructured":"Jones, C. K., Byun, N. & Bubser, M. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology 37, 16\u201342 (2012).","journal-title":"Neuropsychopharmacology"},{"key":"1335_CR101","doi-asserted-by":"publisher","first-page":"7698030","DOI":"10.1155\/2021\/7698030","volume":"2021","author":"JB Ding","year":"2021","unstructured":"Ding, J. B. & Hu, K. Cigarette smoking and schizophrenia: etiology, clinical, pharmacological, and treatment implications. Schizophr. Res. Treat. 2021, 7698030 (2021).","journal-title":"Schizophr. Res. Treat."},{"key":"1335_CR102","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.2147\/NDT.S210199","volume":"15","author":"A Gogos","year":"2019","unstructured":"Gogos, A., Skokou, M., Ferentinou, E. & Gourzis, P. Nicotine consumption during the prodromal phase of schizophrenia \u2013 a review of the literature. Neuropsychiatr. Dis. Treat. 15, 2943\u20132958 (2019).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"1335_CR103","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.neubiorev.2005.02.006","volume":"29","author":"V Kumari","year":"2005","unstructured":"Kumari, V. & Postma, P. Nicotine use in schizophrenia: the self medication hypotheses. Neurosci. Biobehav. Rev. 29, 1021\u20131034 (2005).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"1335_CR104","doi-asserted-by":"publisher","first-page":"338","DOI":"10.2174\/1570159X15666170912110450","volume":"16","author":"M Zoli","year":"2018","unstructured":"Zoli, M., Pucci, S., Vilella, A. & Gotti, C. Neuronal and extraneuronal nicotinic acetylcholine receptors. Curr. Neuropharmacol. 16, 338\u2013349 (2018).","journal-title":"Curr. Neuropharmacol."},{"key":"1335_CR105","doi-asserted-by":"publisher","first-page":"1097857","DOI":"10.3389\/fnins.2023.1097857","volume":"17","author":"A Vilella","year":"2023","unstructured":"Vilella, A. et al. Evidence for a protective effect of the loss of \u03b14-containing nicotinic acetylcholine receptors on A\u03b2-related neuropathology in Tg2576 mice. Front. Neurosci. 17, 1097857 (2023).","journal-title":"Front. Neurosci."},{"key":"1335_CR106","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055886","volume":"8","author":"Q Liu","year":"2013","unstructured":"Liu, Q., Emadi, S., Shen, J. X., Sierks, M. R. & Wu, J. Human \u03b14\u03b22 nicotinic acetylcholine receptor as a novel target of oligomeric \u03b1-synuclein. PLoS One 8, e55886 (2013).","journal-title":"PLoS One"},{"key":"1335_CR107","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/ajmg.b.30470","volume":"144B","author":"LF Martin","year":"2007","unstructured":"Martin, L. F. et al. Sensory gating and alpha-7 nicotinic receptor gene allelic variants in schizoaffective disorder, bipolar type. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B, 611\u2013614 (2007).","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"1335_CR108","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/1096-8628(20010108)105:1<20::AID-AJMG1047>3.0.CO;2-C","volume":"105","author":"R Freedman","year":"2001","unstructured":"Freedman, R. et al. Linkage disequilibrium for schizophrenia at the chromosome 15q13-14 locus of the alpha7-nicotinic acetylcholine receptor subunit gene (CHRNA7). Am. J. Med. Genet. 105, 20\u201322 (2001).","journal-title":"Am. J. Med. Genet."},{"key":"1335_CR109","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nature07229","volume":"455","author":"H Stefansson","year":"2008","unstructured":"Stefansson, H. et al. Large recurrent microdeletions associated with schizophrenia. Nature 455, 232\u2013236 (2008).","journal-title":"Nature"},{"key":"1335_CR110","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/mp.2013.30","volume":"19","author":"AL Guillozet-Bongaarts","year":"2014","unstructured":"Guillozet-Bongaarts, A. L. et al. Altered gene expression in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol. Psychiatry 19, 478\u2013485 (2014).","journal-title":"Mol. Psychiatry"},{"key":"1335_CR111","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s12031-009-9233-4","volume":"40","author":"S Mexal","year":"2010","unstructured":"Mexal, S. et al. Differential regulation of alpha7 nicotinic receptor gene (CHRNA7) expression in schizophrenic smokers. J. Mol. Neurosci. 40, 185\u2013195 (2010).","journal-title":"J. Mol. Neurosci."},{"key":"1335_CR112","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1001\/archpsyc.63.6.630","volume":"63","author":"A Olincy","year":"2006","unstructured":"Olincy, A. et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch. Gen. Psychiatry 63, 630\u2013638 (2006).","journal-title":"Arch. Gen. Psychiatry"},{"key":"1335_CR113","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/01.pra.0000442935.15833.c5","volume":"20","author":"SH Preskorn","year":"2014","unstructured":"Preskorn, S. H. et al. Normalizing effects of EVP-6124, an \u03b1-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J. Psychiatr. Pract. 20, 12\u201324 (2014).","journal-title":"J. Psychiatr. Pract."},{"key":"1335_CR114","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1038\/npp.2014.17","volume":"39","author":"D Umbricht","year":"2014","unstructured":"Umbricht, D. et al. A randomized, placebo-controlled study investigating the nicotinic \u03b17 agonist, RG3487, for cognitive deficits in schizophrenia. Neuropsychopharmacology 39, 1568\u20131577 (2014).","journal-title":"Neuropsychopharmacology"},{"key":"1335_CR115","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/schbul\/sbv072","volume":"42","author":"D Walling","year":"2016","unstructured":"Walling, D. et al. Phase 2 trial of an alpha-7 nicotinic receptor agonist (TC-5619) in negative and cognitive symptoms of schizophrenia. Schizophr. Bull. 42, 335\u2013343 (2016).","journal-title":"Schizophr. Bull."},{"key":"1335_CR116","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.neuropharm.2012.06.040","volume":"64","author":"G Winterer","year":"2013","unstructured":"Winterer, G. et al. Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology 64, 197\u2013204 (2013).","journal-title":"Neuropharmacology"},{"key":"1335_CR117","unstructured":"Rogers, M. B. Encenicline misses endpoints in two phase 3 schizophrenia trials. ALZFORUM www.alzforum.org\/news\/research-news\/encenicline-misses-endpoints-two-phase-3-schizophrenia-trials (2016)."},{"key":"1335_CR118","doi-asserted-by":"publisher","first-page":"108053","DOI":"10.1016\/j.neuropharm.2020.108053","volume":"170","author":"AV Terry Jr.","year":"2020","unstructured":"Terry, A. V. Jr. & Callahan, P. M. \u03b17 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: update on animal and clinical studies and strategies for the future. Neuropharmacology 170, 108053 (2020).","journal-title":"Neuropharmacology"},{"key":"1335_CR119","doi-asserted-by":"publisher","first-page":"631589","DOI":"10.3389\/fpsyt.2021.631589","volume":"12","author":"M Recio-Barbero","year":"2021","unstructured":"Recio-Barbero, M. et al. Cognitive enhancers in schizophrenia: a systematic review and meta-analysis of alpha-7 nicotinic acetylcholine receptor agonists for cognitive deficits and negative symptoms. Front. Psychiatry 12, 631589 (2021). A critical review of the evidence for the alpha-7 nicotinic receptor as a target for cognitive enhancement in schizophrenia.","journal-title":"Front. Psychiatry"},{"key":"1335_CR120","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/0163-7258(93)90027-B","volume":"58","author":"MP Caulfield","year":"1993","unstructured":"Caulfield, M. P. Muscarinic receptors\u2014characterization, coupling and function. Pharmacol. Ther. 58, 319\u2013379 (1993).","journal-title":"Pharmacol. Ther."},{"key":"1335_CR121","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","volume":"54","author":"NC Bodick","year":"1997","unstructured":"Bodick, N. C. et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch. Neurol. 54, 465\u2013473 (1997). This clinical trial demonstrates that xanomeline has substantial effects in reducing behavioural and psychotic symptoms in patients with Alzheimer\u2019s disease.","journal-title":"Arch. Neurol."},{"key":"1335_CR122","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejphar.2008.12.044","volume":"605","author":"JN Heinrich","year":"2009","unstructured":"Heinrich, J. N. et al. Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur. J. Pharmacol. 605, 53\u201356 (2009).","journal-title":"Eur. J. Pharmacol."},{"key":"1335_CR123","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","volume":"165","author":"A Shekhar","year":"2008","unstructured":"Shekhar, A. et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am. J. Psychiatry 165, 1033\u20131039 (2008). Clinical study demonstrating xanomeline\u2019s antipsychotic and pro-cognitive properties in people with schizophrenia.","journal-title":"Am. J. Psychiatry"},{"key":"1335_CR124","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00213-023-06362-2","volume":"240","author":"A Breier","year":"2023","unstructured":"Breier, A., Brannan, S. K., Paul, S. M. & Miller, A. C. Evidence of trospium\u2019s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results. Psychopharmacology 240, 1191\u20131198 (2023).","journal-title":"Psychopharmacology"},{"key":"1335_CR125","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa2017015","volume":"384","author":"SK Brannan","year":"2021","unstructured":"Brannan, S. K. et al. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N. Engl. J. Med. 384, 717\u2013726 (2021). This clinical trial demonstrates that xanomeline, an M1 and M4 muscarinic receptor agonist, with the peripheral muscarinic antagonist trospium chloride, significantly reduces positive, negative and cognitive symptoms in schizophrenia.","journal-title":"N. Engl. J. Med."},{"key":"1335_CR126","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","volume":"403","author":"I Kaul","year":"2024","unstructured":"Kaul, I. et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet 403, 160\u2013170 (2024). The first of two phase III studies confirming the antipsychotic properties of xanomeline\/trospium chloride (KarXT) in people with schizophrenia.","journal-title":"Lancet"},{"key":"1335_CR127","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.0785","author":"I Kaul","year":"2024","unstructured":"Kaul, I. et al. Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial. JAMA Psychiatry https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.0785 (2024).","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"1335_CR128","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1176\/appi.ajp.20240076","volume":"182","author":"WP Horan","year":"2025","unstructured":"Horan, W. P., Sauder, C., Harvey, P. D., Ramsay, I. S., Yohn, S. E., Keefe, R. S. E., Davis, V. G., Paul, S. M. & Brannan, S. K. The impact of xanomeline and trospium chloride on cognitive impairment in acute schizophrenia: replication in pooled data from two phase 3 trials. Am. J. Psychiatry 182(3), 297\u2013306 (2025).","journal-title":"Am. J. Psychiatry"},{"key":"1335_CR129","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.schres.2024.08.001","volume":"274","author":"WP Horan","year":"2024","unstructured":"Horan, W. P. et al. Efficacy of KarXT on negative symptoms in acute schizophrenia: a post hoc analysis of pooled data from 3 trials. Schizophr. Res. 274, 57\u201365 (2024).","journal-title":"Schizophr. Res."},{"key":"1335_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2024.03.014","author":"SM Paul","year":"2024","unstructured":"Paul, S. M., Yohn, S. E., Brannan, S. K., Neugebauer, N. M. & Breier, A. Muscarinic receptor activators as novel treatments for schizophrenia. Biol. Psychiatry https:\/\/doi.org\/10.1016\/j.biopsych.2024.03.014 (2024).","journal-title":"Biol. Psychiatry"},{"key":"1335_CR131","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ejphar.2008.12.020","volume":"603","author":"ML Woolley","year":"2009","unstructured":"Woolley, M. L., Carter, H. J., Gartlon, J. E., Watson, J. M. & Dawson, L. A. Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice. Eur. J. Pharmacol. 603, 147\u2013149 (2009).","journal-title":"Eur. J. Pharmacol."},{"key":"1335_CR132","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1038\/npp.2013.186","volume":"38","author":"ML Watt","year":"2013","unstructured":"Watt, M. L. et al. The muscarinic acetylcholine receptor agonist BuTAC mediates antipsychotic-like effects via the M4 subtype. Neuropsychopharmacology 38, 2717\u20132726 (2013).","journal-title":"Neuropsychopharmacology"},{"key":"1335_CR133","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41199-5","volume":"14","author":"WAC Burger","year":"2023","unstructured":"Burger, W. A. C. et al. Xanomeline displays concomitant orthosteric and allosteric binding modes at the M4 mAChR. Nat. Commun. 14, 5440 (2023).","journal-title":"Nat. Commun."},{"key":"1335_CR134","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s41589-022-01247-5","volume":"19","author":"AS Powers","year":"2023","unstructured":"Powers, A. S. et al. Structural basis of efficacy-driven ligand selectivity at GPCRs. Nat. Chem. Biol. 19, 805\u2013814 (2023). A recent study utilizing molecular dynamics simulations and structural biology that resolves a long-standing mystery as to why and how xanomeline preferentially stimulates M4 mAChRs.","journal-title":"Nat. Chem. Biol."},{"key":"1335_CR135","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.neuropharm.2018.11.029","volume":"146","author":"AG Nair","year":"2019","unstructured":"Nair, A. G. et al. The high efficacy of muscarinic M4 receptor in D1 medium spiny neurons reverses striatal hyperdopaminergia. Neuropharmacology 146, 74\u201383 (2019).","journal-title":"Neuropharmacology"},{"key":"1335_CR136","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.neuron.2017.12.008","volume":"96","author":"MS Moehle","year":"2017","unstructured":"Moehle, M. S. et al. Cholinergic projections to the substantia nigra pars reticulata inhibit dopamine modulation of basal ganglia through the M4 muscarinic receptor. Neuron 96, 1358\u20131372.e4 (2017).","journal-title":"Neuron"},{"key":"1335_CR137","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/npp.2015.189","volume":"41","author":"A Ghoshal","year":"2016","unstructured":"Ghoshal, A. et al. Potentiation of M1 muscarinic receptor reverses plasticity deficits and negative and cognitive symptoms in a schizophrenia mouse model. Neuropsychopharmacology 41, 598\u2013610 (2016).","journal-title":"Neuropsychopharmacology"},{"key":"1335_CR138","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.tips.2019.10.007","volume":"40","author":"SP Moran","year":"2019","unstructured":"Moran, S. P., Maksymetz, J. & Conn, P. J. Targeting muscarinic acetylcholine receptors for the treatment of psychiatric and neurological disorders. Trends Pharmacol. Sci. 40, 1006\u20131020 (2019).","journal-title":"Trends Pharmacol. Sci."},{"key":"1335_CR139","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/mds.27740","volume":"34","author":"MS Moehle","year":"2019","unstructured":"Moehle, M. S. & Conn, P. J. Roles of the M4 acetylcholine receptor in the basal ganglia and the treatment of movement disorders. Mov. Disord. 34, 1089\u20131099 (2019).","journal-title":"Mov. Disord."},{"key":"1335_CR140","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1124\/jpet.108.140350","volume":"327","author":"AE Brady","year":"2008","unstructured":"Brady, A. E. et al. Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J. Pharmacol. Exp. Ther. 327, 941\u2013953 (2008).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1335_CR141","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1021\/cn500128b","volume":"5","author":"M Bubser","year":"2014","unstructured":"Bubser, M. et al. Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents. ACS Chem. Neurosci. 5, 920\u2013942 (2014).","journal-title":"ACS Chem. Neurosci."},{"key":"1335_CR142","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1038\/npp.2014.2","volume":"39","author":"NE Byun","year":"2014","unstructured":"Byun, N. E. et al. Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100. Neuropsychopharmacology 39, 1578\u20131593 (2014).","journal-title":"Neuropsychopharmacology"},{"key":"1335_CR143","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.neuron.2016.08.017","volume":"91","author":"DJ Foster","year":"2016","unstructured":"Foster, D. J. et al. Antipsychotic-like effects of M4 positive allosteric modulators are mediated by CB2 receptor-dependent inhibition of dopamine release. Neuron 91, 1244\u20131252 (2016).","journal-title":"Neuron"},{"key":"1335_CR144","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1016\/S0140-6736(22)01990-0","volume":"400","author":"JH Krystal","year":"2022","unstructured":"Krystal, J. H. et al. Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. Lancet 400, 2210\u20132220 (2022). Placebo-controlled clinical trial demonstrating the antipsychotic activity of an M4 mAChR positive allosteric modulator.","journal-title":"Lancet"},{"key":"1335_CR145","doi-asserted-by":"publisher","first-page":"S332","DOI":"10.1016\/j.biopsych.2025.02.806","volume":"97","author":"J Donello","year":"2025","unstructured":"Donello, J., Walker, G., McEwen, S. & Pondo, M. RL-007, a novel oral neuromodulator, reverses cognitive deficits induced by muscarinic receptor blockade in a translational model of cognitive impairment in rats, dogs and humans. Biol. Psychiatry 97, S332 (2025).","journal-title":"Biol. Psychiatry"},{"key":"1335_CR146","doi-asserted-by":"publisher","first-page":"8966","DOI":"10.1073\/pnas.151105198","volume":"98","author":"B Borowsky","year":"2001","unstructured":"Borowsky, B. et al. Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc. Natl Acad. Sci. USA 98, 8966\u20138971 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1335_CR147","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.ygeno.2004.11.010","volume":"85","author":"L Lindemann","year":"2005","unstructured":"Lindemann, L. et al. Trace amine-associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors. Genomics 85, 372\u2013385 (2005).","journal-title":"Genomics"},{"key":"1335_CR148","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.pharmthera.2017.07.002","volume":"180","author":"MD Berry","year":"2017","unstructured":"Berry, M. D., Gainetdinov, R. R., Hoener, M. C. & Shahid, M. Pharmacology of human trace amine-associated receptors: therapeutic opportunities and challenges. Pharmacol. Ther. 180, 161\u2013180 (2017).","journal-title":"Pharmacol. Ther."},{"key":"1335_CR149","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1124\/mol.60.6.1181","volume":"60","author":"JR Bunzow","year":"2001","unstructured":"Bunzow, J. R. et al. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol. Pharmacol. 60, 1181\u20131188 (2001).","journal-title":"Mol. Pharmacol."},{"key":"1335_CR150","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.tins.2022.10.010","volume":"46","author":"EF Halff","year":"2023","unstructured":"Halff, E. F., Rutigliano, G., Garcia-Hidalgo, A. & Howes, O. D. Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders. Trends Neurosci. 46, 60\u201374 (2023).","journal-title":"Trends Neurosci."},{"key":"1335_CR151","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/0278-5846(94)90024-8","volume":"18","author":"RL O\u2019Reilly","year":"1994","unstructured":"O\u2019Reilly, R. L. & Davis, B. A. Phenylethylamine and schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 18, 63\u201375 (1994).","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"1335_CR152","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.tips.2005.03.007","volume":"26","author":"L Lindemann","year":"2005","unstructured":"Lindemann, L. & Hoener, M. C. A renaissance in trace amines inspired by a novel GPCR family. Trends Pharmacol. Sci. 26, 274\u2013281 (2005).","journal-title":"Trends Pharmacol. Sci."},{"key":"1335_CR153","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/j.euroneuro.2015.08.011","volume":"25","author":"A Harmeier","year":"2015","unstructured":"Harmeier, A. et al. Trace amine-associated receptor 1 activation silences GSK3\u03b2 signaling of TAAR1 and D2R heteromers. Eur. Neuropsychopharmacol. 25, 2049\u20132061 (2015).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"1335_CR154","doi-asserted-by":"publisher","first-page":"8485","DOI":"10.1073\/pnas.1103029108","volume":"108","author":"FG Revel","year":"2011","unstructured":"Revel, F. G. et al. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc. Natl Acad. Sci. USA 108, 8485\u20138490 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1335_CR155","doi-asserted-by":"publisher","first-page":"13185","DOI":"10.3390\/ijms222413185","volume":"22","author":"N Dedic","year":"2021","unstructured":"Dedic, N., Dworak, H., Zeni, C., Rutigliano, G. & Howes, O. D. Therapeutic potential of TAAR1 agonists in schizophrenia: evidence from preclinical models and clinical studies. Int. J. Mol. Sci. 22, 13185 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1335_CR156","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/jpet.119.260281","volume":"371","author":"N Dedic","year":"2019","unstructured":"Dedic, N. et al. SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action. J. Pharmacol. Exp. Ther. 371, 1\u201314 (2019).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1335_CR157","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1056\/NEJMoa1911772","volume":"382","author":"KS Koblan","year":"2020","unstructured":"Koblan, K. S. et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. N. Engl. J. Med. 382, 1497\u20131506 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1335_CR158","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1017\/S109285291900124X","volume":"24","author":"A Krogmann","year":"2019","unstructured":"Krogmann, A. et al. Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. CNS Spectr. 24, 38\u201369 (2019).","journal-title":"CNS Spectr."},{"key":"1335_CR159","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyaf032","author":"M Davidson","year":"2025","unstructured":"Davidson, M., Noel, N., Schmitt, F. & Luthringer, R. Roluperidone monotherapy, a treatment for negative symptoms in schizophrenia. Int. J. Neuropsychopharmacol. https:\/\/doi.org\/10.1093\/ijnp\/pyaf032 (2025).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"1335_CR160","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1176\/appi.ajp.2017.17010122","volume":"174","author":"M Davidson","year":"2017","unstructured":"Davidson, M. et al. Efficacy and safety of MIN-101: a 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia. Am. J. Psychiatry 174, 1195\u20131202 (2017).","journal-title":"Am. J. Psychiatry"},{"key":"1335_CR161","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/schbul\/sbz141","volume":"46","author":"GP Strauss","year":"2020","unstructured":"Strauss, G. P. et al. Network analysis indicates that avolition is the most central domain for the successful treatment of negative symptoms: evidence from the roluperidone randomized clinical trial. Schizophr. Bull. 46, 964\u2013970 (2020).","journal-title":"Schizophr. Bull."},{"key":"1335_CR162","doi-asserted-by":"publisher","first-page":"17m11753","DOI":"10.4088\/JCP.17m11753","volume":"79","author":"RSE Keefe","year":"2018","unstructured":"Keefe, R. S. E. et al. Cognitive effects of MIN-101 in patients with schizophrenia and negative symptoms: results from a randomized controlled trial. J. Clin. Psychiatry 79, 17m11753 (2018).","journal-title":"J. Clin. Psychiatry"},{"key":"1335_CR163","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/schbul\/sbac013","volume":"48","author":"M Davidson","year":"2022","unstructured":"Davidson, M. et al. Efficacy and safety of roluperidone for the treatment of negative symptoms of schizophrenia. Schizophr. Bull. 48, 609\u2013619 (2022).","journal-title":"Schizophr. Bull."},{"key":"1335_CR164","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3390\/ph14010061","volume":"14","author":"E Fedele","year":"2021","unstructured":"Fedele, E. & Ricciarelli, R. Memory enhancers for Alzheimer\u2019s dementia: focus on cGMP. Pharmaceuticals 14, 61 (2021).","journal-title":"Pharmaceuticals"},{"key":"1335_CR165","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1098\/rstb.1990.0164","volume":"329","author":"RG Morris","year":"1990","unstructured":"Morris, R. G., Davis, S. & Butcher, S. P. Hippocampal synaptic plasticity and NMDA receptors: a role in information storage? Philos. Trans. R. Soc. B 329, 187\u2013204 (1990).","journal-title":"Philos. Trans. R. Soc. B"},{"key":"1335_CR166","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-07391-1","volume":"12","author":"E Nelissen","year":"2022","unstructured":"Nelissen, E. et al. The sGC stimulator BAY-747 and activator runcaciguat can enhance memory in vivo via differential hippocampal plasticity mechanisms. Sci. Rep. 12, 3589 (2022).","journal-title":"Sci. Rep."},{"key":"1335_CR167","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1111\/cts.13537","volume":"16","author":"SJW van Kraaij","year":"2023","unstructured":"van Kraaij, S. J. W. et al. First-in-human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS-penetrant soluble guanylyl cyclase stimulator. Clin. Transl. Sci. 16, 1381\u20131395 (2023).","journal-title":"Clin. Transl. Sci."},{"key":"1335_CR168","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1124\/jpet.119.260059","volume":"371","author":"H Rosenbrock","year":"2019","unstructured":"Rosenbrock, H. et al. The novel phosphodiesterase 9\u2009A inhibitor BI 409306 increases cyclic guanosine monophosphate levels in the brain, promotes synaptic plasticity, and enhances memory function in rodents. J. Pharmacol. Exp. Ther. 371, 633\u2013641 (2019).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1335_CR169","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/s41386-021-01016-3","volume":"46","author":"J Scarborough","year":"2021","unstructured":"Scarborough, J. et al. Symptomatic and preventive effects of the novel phosphodiesterase-9 inhibitor BI 409306 in an immune-mediated model of neurodevelopmental disorders. Neuropsychopharmacology 46, 1526\u20131534 (2021).","journal-title":"Neuropsychopharmacology"},{"key":"1335_CR170","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.euroneuro.2018.01.003","volume":"28","author":"V Moschetti","year":"2018","unstructured":"Moschetti, V. et al. The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: overview of three phase I randomised trials in healthy volunteers. Eur. Neuropsychopharmacol. 28, 643\u2013655 (2018).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"1335_CR171","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1093\/schbul\/sby049","volume":"45","author":"D Brown","year":"2019","unstructured":"Brown, D. et al. Evaluation of the efficacy, safety, and tolerability of BI 409306, a novel phosphodiesterase 9 inhibitor, in cognitive impairment in schizophrenia: a randomized, double-blind, placebo-controlled, phase II trial. Schizophr. Bull. 45, 350\u2013359 (2019).","journal-title":"Schizophr. Bull."},{"key":"1335_CR172","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.neubiorev.2021.11.032","volume":"132","author":"MC Lobo","year":"2022","unstructured":"Lobo, M. C., Whitehurst, T. S., Kaar, S. J. & Howes, O. D. New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics. Neurosci. Biobehav. Rev. 132, 324\u2013361 (2022).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"1335_CR173","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/YCO.0000000000000530","volume":"32","author":"TM Laursen","year":"2019","unstructured":"Laursen, T. M. Causes of premature mortality in schizophrenia: a review of literature published in 2018. Curr. Opin. Psychiatry 32, 388\u2013393 (2019). Laursen reviews the factors associated with premature death among individuals diagnosed with schizophrenia.","journal-title":"Curr. Opin. Psychiatry"},{"key":"1335_CR174","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.schres.2010.02.1030","volume":"119","author":"J Bobes","year":"2010","unstructured":"Bobes, J., Arango, C., Garcia-Garcia, M. & Rejas, J. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr. Res. 119, 101\u2013109 (2010).","journal-title":"Schizophr. Res."},{"key":"1335_CR175","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/bs.apha.2017.09.009","volume":"82","author":"JY Khokhar","year":"2018","unstructured":"Khokhar, J. Y., Henricks, A. M., Sullivan, E. D. K. & Green, A. I. Unique effects of clozapine: a pharmacological perspective. Adv. Pharmacol. 82, 137\u2013162 (2018).","journal-title":"Adv. Pharmacol."},{"key":"1335_CR176","first-page":"528","volume":"13","author":"RP Hoffman","year":"2017","unstructured":"Hoffman, R. P. The complex inter-relationship between diabetes and schizophrenia. Curr. Diabetes Rev. 13, 528\u2013532 (2017).","journal-title":"Curr. Diabetes Rev."},{"key":"1335_CR177","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.4088\/JCP.v66n0905","volume":"66","author":"DC Henderson","year":"2005","unstructured":"Henderson, D. C. et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J. Clin. Psychiatry 66, 1116\u20131121 (2005).","journal-title":"J. Clin. Psychiatry"},{"key":"1335_CR178","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1001\/jamapsychiatry.2021.0015","volume":"78","author":"K Hagi","year":"2021","unstructured":"Hagi, K. et al. Association between cardiovascular risk factors and cognitive impairment in people with schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry 78, 510\u2013518 (2021).","journal-title":"JAMA Psychiatry"},{"key":"1335_CR179","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1172\/JCI29069","volume":"116","author":"SE Shoelson","year":"2006","unstructured":"Shoelson, S. E., Lee, J. & Goldfine, A. B. Inflammation and insulin resistance. J. Clin. Investig. 116, 1793\u20131801 (2006).","journal-title":"J. Clin. Investig."},{"key":"1335_CR180","doi-asserted-by":"publisher","first-page":"703452","DOI":"10.3389\/fpsyt.2021.703452","volume":"12","author":"AJ Murray","year":"2021","unstructured":"Murray, A. J., Rogers, J. C., Katshu, M., Liddle, P. F. & Upthegrove, R. Oxidative stress and the pathophysiology and symptom profile of schizophrenia spectrum disorders. Front. Psychiatry 12, 703452 (2021). This study addresses the relationship between oxidative stress and the symptom profile of individuals with schizophrenia.","journal-title":"Front. Psychiatry"},{"key":"1335_CR181","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2165\/00023210-200115040-00004","volume":"15","author":"JK Yao","year":"2001","unstructured":"Yao, J. K., Reddy, R. D. & van Kammen, D. P. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 15, 287\u2013310 (2001).","journal-title":"CNS Drugs"},{"key":"1335_CR182","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0920-9964(01)00334-6","volume":"58","author":"MM Khan","year":"2002","unstructured":"Khan, M. M. et al. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr. Res. 58, 1\u201310 (2002).","journal-title":"Schizophr. Res."},{"key":"1335_CR183","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-11-124","volume":"11","author":"M Raffa","year":"2011","unstructured":"Raffa, M., Atig, F., Mhalla, A., Kerkeni, A. & Mechri, A. Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients. BMC Psychiatry 11, 124 (2011).","journal-title":"BMC Psychiatry"},{"key":"1335_CR184","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s11920-023-01457-1","volume":"25","author":"A Stein","year":"2023","unstructured":"Stein, A., Zhu, C., Du, F. & \u00d6ng\u00fcr, D. Magnetic resonance spectroscopy studies of brain energy metabolism in schizophrenia: progression from prodrome to chronic psychosis. Curr. Psychiatry Rep. 25, 659\u2013669 (2023).","journal-title":"Curr. Psychiatry Rep."},{"key":"1335_CR185","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1126\/science.1148045","volume":"318","author":"MM Behrens","year":"2007","unstructured":"Behrens, M. M. et al. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science 318, 1645\u20131647 (2007).","journal-title":"Science"},{"key":"1335_CR186","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.schres.2019.02.017","volume":"213","author":"JH Cabungcal","year":"2019","unstructured":"Cabungcal, J. H., Steullet, P., Kraftsik, R., Cuenod, M. & Do, K. Q. A developmental redox dysregulation leads to spatio-temporal deficit of parvalbumin neuron circuitry in a schizophrenia mouse model. Schizophr. Res. 213, 96\u2013106 (2019).","journal-title":"Schizophr. Res."},{"key":"1335_CR187","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.biopsych.2020.03.016","volume":"88","author":"DO Perkins","year":"2020","unstructured":"Perkins, D. O., Jeffries, C. D. & Do, K. Q. Potential roles of redox dysregulation in the development of schizophrenia. Biol. Psychiatry 88, 326\u2013336 (2020).","journal-title":"Biol. Psychiatry"},{"key":"1335_CR188","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.117","volume":"6","author":"PS Baumann","year":"2016","unstructured":"Baumann, P. S. et al. Impaired fornix-hippocampus integrity is linked to peripheral glutathione peroxidase in early psychosis. Transl. Psychiatry 6, e859 (2016).","journal-title":"Transl. Psychiatry"},{"key":"1335_CR189","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1038\/sj.npp.1301624","volume":"33","author":"S Lavoie","year":"2008","unstructured":"Lavoie, S. et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 33, 2187\u20132199 (2008).","journal-title":"Neuropsychopharmacology"},{"key":"1335_CR190","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029341","volume":"7","author":"C Carmeli","year":"2012","unstructured":"Carmeli, C., Knyazeva, M. G., Cu\u00e9nod, M. & Do, K. Q. Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial. PLoS One 7, e29341 (2012).","journal-title":"PLoS One"},{"key":"1335_CR191","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.biopsych.2008.03.004","volume":"64","author":"M Berk","year":"2008","unstructured":"Berk, M. et al. N-acetyl cysteine as a glutathione precursor for schizophrenia \u2014 a double-blind, randomized, placebo-controlled trial. Biol. Psychiatry 64, 361\u2013368 (2008).","journal-title":"Biol. Psychiatry"},{"key":"1335_CR192","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/WNF.0000000000000001","volume":"36","author":"M Farokhnia","year":"2013","unstructured":"Farokhnia, M. et al. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. Clin. Neuropharmacol. 36, 185\u2013192 (2013).","journal-title":"Clin. Neuropharmacol."},{"key":"1335_CR193","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.schres.2018.03.012","volume":"199","author":"A Breier","year":"2018","unstructured":"Breier, A. et al. Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders. Schizophr. Res. 199, 395\u2013402 (2018).","journal-title":"Schizophr. Res."},{"key":"1335_CR194","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1017\/S0033291716002932","volume":"47","author":"M Rapado-Castro","year":"2017","unstructured":"Rapado-Castro, M. et al. Cognitive effects of adjunctive N-acetyl cysteine in psychosis. Psychol. Med. 47, 866\u2013876 (2017).","journal-title":"Psychol. Med."},{"key":"1335_CR195","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.pnpbp.2017.11.001","volume":"82","author":"Z Sepehrmanesh","year":"2018","unstructured":"Sepehrmanesh, Z., Heidary, M., Akasheh, N., Akbari, H. & Heidary, M. Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: a double-blind, randomized clinical trial. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 82, 289\u2013296 (2018).","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"1335_CR196","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/schbul\/sbx093","volume":"44","author":"P Conus","year":"2018","unstructured":"Conus, P. et al. N-acetylcysteine in a double-blind randomized placebo-controlled trial: toward biomarker-guided treatment in early psychosis. Schizophr. Bull. 44, 317\u2013327 (2018). Treatment with the antioxidant and glutathione precursor N-acetylcysteine reduces markers of oxidative stress and improves cognitive function in individuals with schizophrenia.","journal-title":"Schizophr. Bull."},{"key":"1335_CR197","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.schres.2017.07.008","volume":"191","author":"C Retsa","year":"2018","unstructured":"Retsa, C. et al. Treatment in early psychosis with N-acetyl-cysteine for 6 months improves low-level auditory processing: pilot study. Schizophr. Res. 191, 80\u201386 (2018).","journal-title":"Schizophr. Res."},{"key":"1335_CR198","doi-asserted-by":"publisher","DOI":"10.2174\/0109298673365458250901115725","author":"D Marazziti","year":"2025","unstructured":"Marazziti, D., Caruso, V., Cappellato, G., Chiarantini, I., Gurrieri, R., Perrone, P., Violi, M., Crivelli, N. S. B., Weiss, F. & Perugi, G. The emerging role of N-acetylcysteine in psychiatry: a narrative review of available data. Curr. Med. Chem. https:\/\/doi.org\/10.2174\/0109298673365458250901115725 (2025).","journal-title":"Curr. Med. Chem."},{"key":"1335_CR199","doi-asserted-by":"publisher","DOI":"10.1097\/yco.0000000000000952","author":"M Trott","year":"2024","unstructured":"Trott, M., Arnautovska, U. & Siskind, D. GLP-1 receptor agonists and weight loss in schizophrenia - past, present, and future. Curr. Opin. Psychiatry https:\/\/doi.org\/10.1097\/yco.0000000000000952 (2024). The authors review the evidence of the utility of GLP-1 agonists in mitigating the weight gain and metabolic consequence in individuals with schizophrenia.","journal-title":"Curr. Opin. Psychiatry"},{"key":"1335_CR200","doi-asserted-by":"publisher","first-page":"204512532311651","DOI":"10.1177\/20451253231165169","volume":"13","author":"F Prasad","year":"2023","unstructured":"Prasad, F. et al. Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin \u2013 a case series. Ther. Adv. Psychopharmacol. 13, 20451253231165169 (2023).","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"1335_CR201","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1176\/appi.ajp.2013.12010127","volume":"170","author":"LF Jarskog","year":"2013","unstructured":"Jarskog, L. F. et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am. J. Psychiatry 170, 1032\u20131040 (2013).","journal-title":"Am. J. Psychiatry"},{"key":"1335_CR202","first-page":"S8","volume":"67","author":"J Anderson","year":"2018","unstructured":"Anderson, J. The Pharmacokinetic properties of glucagon-like peptide-1 receptor agonists and their mode and mechanism of action in patients with type 2 diabetes. J. Fam. Pract. 67, S8\u2013S13 (2018).","journal-title":"J. Fam. Pract."},{"key":"1335_CR203","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1001\/jama.2024.1017","volume":"331","author":"R Rubin","year":"2024","unstructured":"Rubin, R. Could GLP-1 receptor agonists like semaglutide treat addiction, Alzheimer disease, and other conditions? JAMA 331, 1519\u20131521 (2024).","journal-title":"JAMA"},{"key":"1335_CR204","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"WG Meissner","year":"2024","unstructured":"Meissner, W. G. et al. Trial of lixisenatide in early Parkinson\u2019s disease. N. Engl. J. Med. 390, 1176\u20131185 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1335_CR205","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00429-020-02189-1","volume":"226","author":"E Farkas","year":"2021","unstructured":"Farkas, E. et al. Distribution and ultrastructural localization of the glucagon-like peptide-1 receptor (GLP-1R) in the rat brain. Brain Struct. Funct. 226, 225\u2013245 (2021).","journal-title":"Brain Struct. Funct."},{"key":"1335_CR206","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.genhosppsych.2022.07.006","volume":"78","author":"K Lee","year":"2022","unstructured":"Lee, K., Abraham, S. & Cleaver, R. A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. Gen. Hosp. Psychiatry 78, 58\u201367 (2022).","journal-title":"Gen. Hosp. Psychiatry"},{"key":"1335_CR207","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.orcp.2020.11.002","volume":"15","author":"M Tham","year":"2021","unstructured":"Tham, M., Chong, T. W. H., Jenkins, Z. M. & Castle, D. J. The use of anti-obesity medications in people with mental illness as an adjunct to lifestyle interventions \u2014 effectiveness, tolerability and impact on eating behaviours: a 52-week observational study. Obes. Res. Clin. Pract. 15, 49\u201357 (2021).","journal-title":"Obes. Res. Clin. Pract."},{"key":"1335_CR208","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1001\/jamapsychiatry.2025.2332","volume":"82","author":"AA Ganeshalingram","year":"2025","unstructured":"Ganeshalingram, A. A. et al. Semaglutide treatment of antipsychotic-treated patients with schizophrenia, prediabetes and obesity: the HISTORI randomized clinical trial. JAMA Psychiatry 82, 1065\u20131074 (2025).","journal-title":"JAMA Psychiatry"},{"key":"1335_CR209","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41386-023-01614-3","volume":"49","author":"JE Hanson","year":"2024","unstructured":"Hanson, J. E. et al. Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry. Neuropsychopharmacology 49, 51\u201366 (2024).","journal-title":"Neuropsychopharmacology"},{"key":"1335_CR210","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/j.neubiorev.2013.06.001","volume":"37","author":"P Fusar-Poli","year":"2013","unstructured":"Fusar-Poli, P. et al. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci. Biobehav. Rev. 37, 1680\u20131691 (2013).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"1335_CR211","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.neuint.2014.05.015","volume":"75","author":"DT Balu","year":"2014","unstructured":"Balu, D. T. & Coyle, J. T. Chronic D-serine reverses arc expression and partially rescues dendritic abnormalities in a mouse model of NMDA receptor hypofunction. Neurochem. Int. 75, 76\u201378 (2014).","journal-title":"Neurochem. Int."},{"key":"1335_CR212","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001694","volume":"20","author":"C Haass","year":"2022","unstructured":"Haass, C. & Selkoe, D. If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline? PLoS Biol. 20, e3001694 (2022).","journal-title":"PLoS Biol."},{"key":"1335_CR213","unstructured":"The Schizophrenia Working Group of the Psychiatric Genomics Consortium, Ripke, S., Walters, J. T. R. & O\u2019Donovan, M. C. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. Nature 604, 502\u2013508 (2022)."},{"key":"1335_CR214","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nature13595","volume":"511","author":"Schizophrenia Working Group of the Psychiatric Genomics Consortium","year":"2014","unstructured":"Schizophrenia Working Group of the Psychiatric Genomics Consortium Biological insights from 108 schizophrenia-associated genetic loci. Nature 511, 421\u2013427 (2014).","journal-title":"Nature"},{"key":"1335_CR215","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41589-019-0453-9","volume":"16","author":"SJ Bradley","year":"2020","unstructured":"Bradley, S. J. et al. Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs. Nat. Chem. Biol. 16, 240\u2013249 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"1335_CR216","doi-asserted-by":"publisher","first-page":"7356","DOI":"10.3390\/ijms24087356","volume":"24","author":"D Wang","year":"2023","unstructured":"Wang, D. et al. Structural insights into M1 muscarinic acetylcholine receptor signaling bias between G\u03b1q and \u03b2-arrestin through BRET assays and molecular docking. Int. J. Mol. Sci. 24, 7356 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1335_CR217","unstructured":"Delay, J. & Deniker, P. Le traitement des psychoses par une m\u00e9thode neurolytique d\u00e9riv\u00e9e de l'hibernoth\u00e9rapie. (le 4560 RP. utilis\u00e9 seul en cure prolong\u00e9e et continue). In Comptes-rendus du Congr\u00e8s de Psychiatrie et de Neurologie de langue fran\u00e7aise. Luxembourg Congr\u00e8s de Psychiatrie et de Neurologie de langue fran\u00e7aise (Masson, 1952). Report of the efficacy of chlorpromazine in the treatment of schizophrenia."},{"key":"1335_CR218","first-page":"841","volume":"17","author":"PA Janssen","year":"1967","unstructured":"Janssen, P. A., Niemegeers, C. J., Schellekens, K. H. & Lenaerts, F. M. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data? IV. An improved experimental design for measuring the inhibitory effects of neuroleptic drugs on amphetamine-or apomorphine-induced \u201cCheroing\u201d and \u201cagitation\u201d in rats. Arzneimittelforschung 17, 841\u2013854 (1967).","journal-title":"Arzneimittelforschung"},{"key":"1335_CR219","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1600-0773.1963.tb01730.x","volume":"20","author":"A Carlsson","year":"1963","unstructured":"Carlsson, A. & Lindqvist, M. Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. 20, 140\u2013144 (1963). Proposal that antipsychotic drugs act by blocking dopamine receptors.","journal-title":"Acta Pharmacol. Toxicol."},{"key":"1335_CR220","first-page":"663","volume":"1","author":"SH Snyder","year":"1975","unstructured":"Snyder, S. H., Creese, I. & Burt, D. R. The brain\u2019s dopamine receptor: labeling with (3H) dopamine and (3H) haloperidol. Psychopharmacol. Commun. 1, 663\u2013673 (1975).","journal-title":"Psychopharmacol. Commun."},{"key":"1335_CR221","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1176\/ajp.133.2.197","volume":"133","author":"SH Snyder","year":"1976","unstructured":"Snyder, S. H. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am. J. Psychiatry 133, 197\u2013202 (1976).","journal-title":"Am. J. Psychiatry"},{"key":"1335_CR222","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 3rd edn (The American Psychiatric Association, 1985)."},{"key":"1335_CR223","doi-asserted-by":"publisher","first-page":"113004","DOI":"10.1016\/j.bbr.2020.113004","volume":"398","author":"P Cumming","year":"2021","unstructured":"Cumming, P., Abi-Dargham, A. & Gr\u00fcnder, G. Molecular imaging of schizophrenia: neurochemical findings in a heterogeneous and evolving disorder. Behav. Brain Res. 398, 113004 (2021).","journal-title":"Behav. Brain Res."},{"key":"1335_CR224","doi-asserted-by":"publisher","first-page":"s13","DOI":"10.1192\/bjp.191.51.s13","volume":"51","author":"OD Howes","year":"2007","unstructured":"Howes, O. D. et al. Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br. J. Psychiatry 51, s13\u2013s18 (2007).","journal-title":"Br. J. Psychiatry"},{"key":"1335_CR225","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1001\/archgenpsychiatry.2012.169","volume":"69","author":"OD Howes","year":"2012","unstructured":"Howes, O. D. et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch. Gen. Psychiatry 69, 776\u2013786 (2012).","journal-title":"Arch. Gen. Psychiatry"},{"key":"1335_CR226","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/mp.2017.16","volume":"22","author":"AH Ashok","year":"2017","unstructured":"Ashok, A. H. et al. The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Mol. Psychiatry 22, 666\u2013679 (2017).","journal-title":"Mol. Psychiatry"},{"key":"1335_CR227","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3389\/fpsyt.2018.00622","volume":"9","author":"NE MacKenzie","year":"2018","unstructured":"MacKenzie, N. E. et al. Antipsychotics, metabolic adverse effects, and cognitive function in schizophrenia. Front. Psychiatry 9, 622 (2018).","journal-title":"Front. Psychiatry"},{"key":"1335_CR228","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2174\/1568007024606212","volume":"1","author":"JT Coyle","year":"2002","unstructured":"Coyle, J. T., Tsai, G. & Goff, D. C. Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr. Drug Targets CNS Neurol. Disord. 1, 183\u2013189 (2002).","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"1335_CR229","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1176\/ajp.151.8.1234","volume":"151","author":"DC Javitt","year":"1994","unstructured":"Javitt, D. C., Zylberman, I., Zukin, S. R., Heresco-Levy, U. & Lindenmayer, J. P. Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry 151, 1234\u20131236 (1994).","journal-title":"Am. J. Psychiatry"},{"key":"1335_CR230","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1192\/bjp.169.5.610","volume":"169","author":"U Heresco-Levy","year":"1996","unstructured":"Heresco-Levy, U. et al. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br. J. Psychiatry 169, 610\u2013617 (1996).","journal-title":"Br. J. Psychiatry"},{"key":"1335_CR231","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/archpsyc.56.1.29","volume":"56","author":"U Heresco-Levy","year":"1999","unstructured":"Heresco-Levy, U. et al. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry 56, 29\u201336 (1999).","journal-title":"Arch. Gen. Psychiatry"},{"key":"1335_CR232","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2174\/1570159X14666160225154812","volume":"15","author":"DC Goff","year":"2017","unstructured":"Goff, D. C. D-cycloserine in schizophrenia: new strategies for improving clinical outcomes by enhancing plasticity. Curr. Neuropharmacol. 15, 21\u201334 (2017).","journal-title":"Curr. Neuropharmacol."},{"key":"1335_CR233","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/0006-8993(90)90745-W","volume":"510","author":"GB Watson","year":"1990","unstructured":"Watson, G. B., Bolanowski, M. A., Baganoff, M. P., Deppeler, C. L. & Lanthorn, T. H. D-Cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res. 510, 158\u2013160 (1990).","journal-title":"Brain Res."},{"key":"1335_CR234","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/0304-3940(92)90081-H","volume":"146","author":"J Sirvi\u00f6","year":"1992","unstructured":"Sirvi\u00f6, J., Ekonsalo, T., Riekkinen, P. Jr, Lahtinen, H. & Riekkinen, P. D-cycloserine, a modulator of the N-methyl-D-aspartate receptor, improves spatial learning in rats treated with muscarinic antagonist. Neurosci. Lett. 146, 215\u2013218 (1992).","journal-title":"Neurosci. Lett."},{"key":"1335_CR235","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1176\/ajp.152.8.1213","volume":"152","author":"DC Goff","year":"1995","unstructured":"Goff, D. C., Tsai, G., Manoach, D. S. & Coyle, J. T. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am. J. Psychiatry 152, 1213\u20131215 (1995).","journal-title":"Am. J. Psychiatry"},{"key":"1335_CR236","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0920-9964(01)00220-1","volume":"56","author":"AE Evins","year":"2002","unstructured":"Evins, A. E., Amico, E., Posever, T. A., Toker, R. & Goff, D. C. D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr. Res. 56, 19\u201323 (2002).","journal-title":"Schizophr. Res."},{"key":"1335_CR237","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S0006-3223(98)00367-9","volume":"45","author":"DC Goff","year":"1999","unstructured":"Goff, D. C., Henderson, D. C., Evins, A. E. & Amico, E. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol. Psychiatry 45, 512\u2013514 (1999).","journal-title":"Biol. Psychiatry"},{"key":"1335_CR238","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s00213-004-2032-2","volume":"179","author":"DC Goff","year":"2005","unstructured":"Goff, D. C. et al. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology 179, 144\u2013150 (2005).","journal-title":"Psychopharmacology"},{"key":"1335_CR239","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/0014-2999(94)90687-4","volume":"257","author":"D Quartermain","year":"1994","unstructured":"Quartermain, D., Mower, J., Rafferty, M. F., Herting, R. L. & Lanthorn, T. H. Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur. J. Pharmacol. 257, 7\u201312 (1994).","journal-title":"Eur. J. Pharmacol."},{"key":"1335_CR240","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.schres.2014.01.016","volume":"153","author":"CK Cain","year":"2014","unstructured":"Cain, C. K. et al. d-Cycloserine augmentation of cognitive remediation in schizophrenia. Schizophr. Res. 153, 177\u2013183 (2014).","journal-title":"Schizophr. Res."},{"key":"1335_CR241","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.schres.2011.05.029","volume":"131","author":"JD Gottlieb","year":"2011","unstructured":"Gottlieb, J. D. et al. D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia. Schizophr. Res. 131, 69\u201374 (2011).","journal-title":"Schizophr. Res."},{"key":"1335_CR242","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/j.1471-4159.1993.tb03219.x","volume":"60","author":"A Hashimoto","year":"1993","unstructured":"Hashimoto, A., Nishikawa, T., Oka, T. & Takahashi, K. Endogenous D-serine in rat brain: N-methyl-D-aspartate receptor-related distribution and aging. J. Neurochem. 60, 783\u2013786 (1993).","journal-title":"J. Neurochem."},{"key":"1335_CR243","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S0026-895X(25)09633-6","volume":"36","author":"CJ McBain","year":"1989","unstructured":"McBain, C. J., Kleckner, N. W., Wyrick, S. & Dingledine, R. Structural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in xenopus oocytes. Mol. Pharmacol. 36, 556\u2013565 (1989).","journal-title":"Mol. Pharmacol."},{"key":"1335_CR244","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S0006-3223(98)00279-0","volume":"44","author":"G Tsai","year":"1998","unstructured":"Tsai, G., Yang, P., Chung, L. C., Lange, N. & Coyle, J. T. D-serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 44, 1081\u20131089 (1998).","journal-title":"Biol. Psychiatry"},{"key":"1335_CR245","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.biopsych.2004.12.037","volume":"57","author":"U Heresco-Levy","year":"2005","unstructured":"Heresco-Levy, U. et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol. Psychiatry 57, 577\u2013585 (2005).","journal-title":"Biol. Psychiatry"},{"key":"1335_CR246","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.schres.2010.05.012","volume":"121","author":"JT Kantrowitz","year":"2010","unstructured":"Kantrowitz, J. T. et al. High dose D-serine in the treatment of schizophrenia. Schizophr. Res. 121, 125\u2013130 (2010).","journal-title":"Schizophr. Res."},{"key":"1335_CR247","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nature01497","volume":"422","author":"Y Nong","year":"2003","unstructured":"Nong, Y. et al. Glycine binding primes NMDA receptor internalization. Nature 422, 302\u2013307 (2003).","journal-title":"Nature"},{"key":"1335_CR248","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1177\/0269881120965937","volume":"35","author":"KK Goh","year":"2021","unstructured":"Goh, K. K., Wu, T. H., Chen, C. H. & Lu, M. L. Efficacy of N-methyl-D-aspartate receptor modulator augmentation in schizophrenia: a meta-analysis of randomised, placebo-controlled trials. J. Psychopharmacol. 35, 236\u2013252 (2021). The largest meta-analysis to date; this demonstrates that agonists at the glycine modulatory site on NMDARs significantly reduce negative, cognitive and positive symptoms in patients with schizophrenia on antipsychotic drugs.","journal-title":"J. Psychopharmacol."}],"updated-by":[{"DOI":"10.1038\/s41573-026-01409-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000}}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-025-01335-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-025-01335-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-025-01335-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T12:04:09Z","timestamp":1775563449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-025-01335-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":248,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1335"],"URL":"https:\/\/doi.org\/10.1038\/s41573-025-01335-w","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"3 November 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41573-026-01409-3","URL":"https:\/\/doi.org\/10.1038\/s41573-026-01409-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.T.C. is a founder of Waveform Bioscience, a member of the Scientific Advisory Board of SyneuRx and a consultant to Response Pharmaceuticals. S.M.P. is a former employee and shareholder of Karuna Therapeutics (now Bristol Myers Squibb); a cofounder and shareholder of Sage Therapeutics, Voyager Therapeutics, Rapport Therapeutics and Seaport Therapeutics; a shareholder of Alnylam Pharmaceuticals and Eli Lilly and Company; and a venture partner at Third Rock Ventures. Since the inception of this manuscript, he has had no financial interests in Cobenfy and its marketing.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}